HDMAPP (ammonium salt)
(Synonyms: HMBPP) 目录号 : GC43807A phosphoantigen for Vγ9Vδ2 T cells
Cas No.:443892-56-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >90.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
HDMAPP is a metabolite of the microbial dioxyxylulose-phosphate pathway, which is analogous to the isopentenyl pyrophosphate pathway in mammals. It is a protease-resistant and phosphatase-sensitive pyrophosphate produced by bacteria and plants.[1] [2] HDMAPP is a non-peptide ligand, also called a phosphoantigen, that binds the T cell receptor on Vγ9Vδ2 peripheral blood lymphocytes with high affinity (EC50 = 0.39 nM).[3] It induces the expansion of human memory Vγ9Vδ2 T cells, but does not increase their ability to inhibit intracellular mycobacterial growth.[4][5] Neonatal Vγ9Vδ2 T cells require micromolar concentrations of HDMAPP to drive expansion.[6]
Reference:
[1]. Poupot, M., and Fournié, J.J. Non-peptide antigens activating human Vg9/Vd2 T lymphocytes. Immunology Letters 95, 129-138 (2004).
[2]. Tanaka, Y., Morita, C.T., Tanaka, Y., et al. Natural and synthetic non-peptide antigens recognized by humanγδT cells. Nature 375, 155-158 (1995).
[3]. Boëdec, A., Sicard, H., Dessolin, J., et al. Synthesis and biological activity of phosphonate analogues and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate. Journal of Medicinal Chemistry 51, 1747-1754 (2008).
[4]. DeBarros, A., Chevas-Ferreira, M., d'Orey, F., et al. CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human γδ peripheral blood lymphocytes. European Journal of Immunology 41(1), 195-201 (2011).
[5]. Spencer, C.T., Abate, G., Blazevic, A., et al. Only a subset of phosphoantigen-responsive γ9δ2 T cells mediate protective TB immunity. Journal of Immunology 181(7), 4471-4484 (2008).
[6]. Moens, E., Brouwer, M., Dimova, T., et al. IL-23R and TCR signaling drives the generation of neonatal Vγ9Vδ2 T cells expressing high levels of cytotoxic mediators and producing IFN-γ and IL-17. Journal of Leukocyte Biology 89(5), 743-752 (2011).
Cas No. | 443892-56-6 | SDF | |
别名 | HMBPP | ||
化学名 | mono[(2E)-hydroxy-3-methyl-2-butenyl] ester diphosphoric acid, triammonium salt | ||
Canonical SMILES | [O-]P(OP([O-])(OC/C=C(CO)\C)=O)([O-])=O.[NH4+].[NH4+].[NH4+] | ||
分子式 | C5H9O8P2•3NH4 | 分子量 | 313.2 |
溶解度 | PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.1928 mL | 15.9642 mL | 31.9285 mL |
5 mM | 0.6386 mL | 3.1928 mL | 6.3857 mL |
10 mM | 0.3193 mL | 1.5964 mL | 3.1928 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。